Lv5
1140 积分 2022-06-29 加入
An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer
14天前
已完结
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (DUO-E/GOG-3041/ENGOT-EN10): Objective response rate and duration of response by mismatch repair status
21天前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
21天前
已完结
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
25天前
已完结
Book review: Tsiatis, A.A. 2006: Semiparametric Theory and Missing Data. Springer
1个月前
已完结
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
1个月前
已完结
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en‑dpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial
1个月前
已完结
Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
1个月前
已完结
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
皖公网安备34019202002308
